Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in ...

On a mission to expand its recently approved Tryngolza beyond the rare genetic disorder familial chylomicronemia syndrome ...

Ionis Pharmaceuticals has reported positive topline outcomes from the randomised, global Phase III Essence study of Tryngolza ...

Reducing the levels of triglycerides and triglyceride-rich lipoproteins remains an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III ...

Olezarsen is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.

Topline results from the Essence study show that olezarsen significantly lowered mean triglyceride levels compared to placebo ...

Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, a condition that increases the risk of coronary artery disease. The triglycerides found in ...

Topline data were announced from a phase 3 trial evaluating olezarsen in patients with moderate hypertriglyceridemia with or at risk for ASCVD.

The late-stage results come in advance of pivotal data that Ionis expects to provide for its antisense oligonucleotide ...

One common inherited condition is called familial hypertriglyceridemia. You can also have high triglycerides for other reasons, especially if you're overweight, have an unhealthy diet, and aren't ...

Mammoth Biosciences Inc. has nominated its first clinical development candidate – MB-111 – a potential one-time treatment for patients with very high triglycerides, including familial chylomicronemia ...

CSPC Pharmaceutical Group Ltd.’s anti-βKlotho monoclonal antibody drug JMT-202 has received clearance from China’s National Medical Products Administration (NMPA) to enter clinical trials to lower ...